Tag

Sentynl Therapeutics, Inc.

1 article

Zydus Subsidiary Sentynl Licenses Mereo's Alvelestat for AATD

Zydus Lifesciences subsidiary Sentynl Therapeutics enters option and license agreement with Mereo BioPharma for U.S. rights to alvelestat, a Phase 3-ready treatment for rare lung disease AATD-LD. Mere